Interprofessional Care of Patients with ROS1 Non-Small Cell Lung Cancer

To participate in this activity, please:

Log in Sign Up

Molecular alterations and ROS1 rearrangements, along with sequencing and safety considerations, play critical roles in personalizing targeted treatment in patients with ROS1 non-small cell lung cancer. To further enhance the benefits of targeted therapy, and improve patient health outcomes, care provided by an interprofessional, multidisciplinary team is needed. The benefits of interprofessional collaboration are described with real-world strategies for success.

Course Credit:

0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours

Dates:

Opens: 2025-10-31
Closes: 2026-10-31

Target Audience:

Nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients with ROS1 non-small cell lung cancer.

This activity was self-funded by Annenberg Center for Health Sciences.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 hours AAPA Category 1 CME credits. Approval is valid until October 31, 2026. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.25 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and Pharmacosmos


Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Contributing Faculty

  • Jonathan Dowell, MD

    Professor, Department of Internal Medicine
    UT Southwestern Medical Center
    Dallas, Texas

  • Christopher Flores, MD

    Family Medicine Physician
    Eisenhower Medical Center
    Rancho Mirage, California

  • LaTosha Mollette, DNP

    Family Nurse Practitioner
    Louisiana Family Medicine Clinic
    Jonesboro, Louisiana

  • Michael Smith, PharmD

    Clinical Pharmacist in Pain/Palliative Care
    University of Michigan
    Ann Arbor, Michigan

Learning Objectives

  • Describe the evolution in the treatment landscape for patients with ROS1 rearranged NSCLC.
  • Identify strategies to improve interprofessional care of patients with cancer, including ROS1 NSCLC.

Faculty Disclosures

Jonathan Dowell, MD

Advisory Board: Catalyst, Regeneron, Takeda


Christopher Flores, MD

No relationships to disclose.

LaTosha Mollette, DNP

No relationships to disclose.

Michael Smith, PharmD

No relationships to disclose.